- cafead   Jan 25, 2024 at 09:12: PM
via Bristol Myers Squibb is proving its worth as an M&A competitor, coming out on top not once but twice in terms of fresh acquisitions. Most recently, the pharma’s $4.1 billion bid for radiopharmaceuticals biotech RayzeBio was enough to beat out two other companies that also put down offers.
article source
article source